LUCD Lucid Diagnostics Inc.
USHealthcareAs of 2026-07-10 16:00
Why LUCD matters now
Lucid Diagnostics Inc. (LUCD) is a US stock in Healthcare. The latest InvestLog snapshot shows $1.00 with +0.99% on the session and $102.3M in market capitalization; recent performance reads 1-month +14.04% and YTD -0.92%.
The latest financial table shown here is Q1 2026, with revenue of $1.3M, net income of $-13.9M, and EPS of $-0.17. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -42.0%.
The latest indexable market news headline is "Lucid Diagnostics: Positioned For A Medicare-Driven Inflection" from Seeking Alpha.
Additional event context on this page matters because analyst consensus is Buy with a median target of $2.00; recent insider activity includes Matheis Dennis filing P-Purchase. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
27.53
P/S
21.52
EV/EBITDA
-2.48
DCF Value
$-2.92
FCF Yield
-42.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
-40.0%
Operating Margin
-959.6%
Net Margin
-876.7%
ROE
-370.2%
ROA
-132.1%
ROIC
-159.9%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $1.3M | $-13.9M | $-0.17 |
| Q4 2025 | $1.5M | $-16.3M | $-0.12 |
| FY 2025 | $4.7M | $-58.0M | $-0.69 |
| Q3 2025 | $1.2M | $-10.4M | $-0.10 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$2.00
Target (Median)
$2.00
Target Range
$2.00 - $2.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Medical - Devices
Country
US
Exchange
—
Beta
1.08
Lucid Diagnostics Inc. is a commercial-stage medical technology firm focused on diagnostic solutions. The company's primary objective is to serve patients afflicted with gastroesophageal reflux disease (GERD), commonly referred to as chronic heartburn or acid reflux, especially those at increased risk of developing precancerous esophageal conditions or the particularly aggressive esophageal adenocarcinoma. Their key product offerings include EsoGuard, an internally developed esophageal DNA test, and EsoCheck, a specialized device designed for collecting esophageal cells. Formed in 2018, Lucid Diagnostics Inc. has its headquarters in New York, New York, and operates as a subsidiary of PAVmed Inc.